We are live on
!
Find out more
Mitsubishi UFJ Asset Management Portfolio holdings
AUM
$180B
1-Year Est. Return
37.51%
This Fund
S&P 500
This Quarter
Est. Return
-2.8%
1 Year Est. Return
+37.51%
3 Year Est. Return
+115.4%
5 Year Est. Return
+142.39%
10 Year Est. Return
+552.78%
AUM
$49.4B
AUM Growth
+$1.51B
(+3.2%)
Cap. Flow
+$3.38B
Cap. Flow
% of AUM
6.84%
Top 10 Holdings %
Top 10 Hldgs %
27.38%
Holding
1,558
New
448
Increased
789
Reduced
207
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$187M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$153M |
| 3 |
Microsoft
MSFT
|
+$124M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$118M |
| 5 |
Coca-Cola
KO
|
+$101M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adobe
ADBE
|
+$64.4M |
| 2 |
Danaher
DHR
|
+$32.3M |
| 3 |
Amphenol
APH
|
+$28.2M |
| 4 |
State Street SPDR Bloomberg High Yield Bond ETF
JNK
|
+$26.9M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.75% |
| 2 | Healthcare | 16.06% |
| 3 | Financials | 13.69% |
| 4 | Consumer Discretionary | 8.75% |
| 5 | Consumer Staples | 7.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Recursion Pharmaceuticals
RXRX
$1.78B
| $252K | ﹤0.01% |
33,002
+1,938
| +6% | +$19.3K |
|
1002
Roivant Sciences
ROIV
$26.2B
| $251K | ﹤0.01% |
21,450
| – | – |
|
1003
Regenxbio
RGNX
$704M
| $239K | ﹤0.01% |
14,539
+870
| +6% | +$15.8K |
|
|
BLUE
1004
DELISTED
bluebird bio
BLUE
| $237K | ﹤0.01% |
3,900
+238
| +6% | +$16.7K |
|
1005
Ionis Pharmaceuticals
IONS
$9.28B
| $236K | ﹤0.01% |
5,195
+95
| +2% | +$3.92K |
|
|
DHC
1006
Diversified Healthcare Trust
DHC
$2.03B
| $236K | ﹤0.01% |
121,394
-28,212
| -19% | -$71.5K |
|
1007
Editas Medicine
EDIT
$432M
| $229K | ﹤0.01% |
29,387
| – | – |
|
1008
Sarepta Therapeutics
SRPT
$1.95B
| $228K | ﹤0.01% |
1,881
+43
| +2% | +$4.86K |
|
1009
Marqeta
MQ
$1.71B
| $225K | ﹤0.01% |
9,394
-746
| -7% | -$16.9K |
|
1010
Forum Energy Technologies
FET
$927M
| $224K | ﹤0.01% |
9,341
-363
| -4% | -$9.05K |
|
|
SOL
1011
DELISTED
Emeren Group
SOL
| $223K | ﹤0.01% |
72,247
+408
| +0.6% | +$1.42K |
|
|
ALX
1012
Alexander's
ALX
$1.4B
| $220K | ﹤0.01% |
1,205
+18
| +2% | +$3.4K |
|
|
VERV
1013
DELISTED
Verve Therapeutics
VERV
| $219K | ﹤0.01% |
16,479
+871
| +6% | +$14K |
|
1014
Intellia Therapeutics
NTLA
$1.66B
| $210K | ﹤0.01% |
6,651
+451
| +7% | +$17.5K |
|
1015
Arrowhead Research
ARWR
$12.1B
| $209K | ﹤0.01% |
7,762
+210
| +3% | +$6.43K |
|
1016
Xencor
XNCR
$1.71B
| $208K | ﹤0.01% |
10,347
+369
| +4% | +$8.39K |
|
1017
Q2 Holdings
QTWO
$4.13B
| $208K | ﹤0.01% |
6,458
-368
| -5% | -$12.2K |
|
1018
Sanofi
SNY
$105B
| $208K | ﹤0.01% |
3,880
+418
| +12% | +$22.3K |
|
|
CVAC
1019
DELISTED
CureVac
CVAC
| $208K | ﹤0.01% |
30,435
+1,635
| +6% | +$14.4K |
|
1020
Maravai LifeSciences
MRVI
$861M
| $206K | ﹤0.01% |
20,619
+1,170
| +6% | +$12.8K |
|
1021
CRISPR Therapeutics
CRSP
$5.22B
| $204K | ﹤0.01% |
4,484
+76
| +2% | +$3.92K |
|
1022
Novartis
NVS
$288B
| $203K | ﹤0.01% |
1,995
+105
| +6% | +$10.7K |
|
1023
Ultragenyx Pharmaceutical
RARE
$2.6B
| $198K | ﹤0.01% |
5,568
+79
| +1% | +$3.13K |
|
|
ONL
1024
Orion Office REIT
ONL
$161M
| $197K | ﹤0.01% |
37,889
| – | – |
|
1025
4D Molecular Therapeutics
FDMT
$609M
| $194K | ﹤0.01% |
15,278
+820
| +6% | +$13.7K |
|
Similar funds
Mitsubishi UFJ Asset Management's Q3 2023 Portfolio in Review
As of Q3 2023, Mitsubishi UFJ Asset Management held 1,558 positions worth $49.4B, up 3.2% from $47.9B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Mitsubishi UFJ Asset Management deployed $3.38B of net new capital in Q3 2023, opening 448 new positions and adding to 789 existing holdings. Its largest new stake was Kenvue: 1,857,745 shares worth $37.3M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, down from 29% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Adobe, an estimated $64.4M trimmed.
- Mitsubishi UFJ Asset Management's largest Q3 2023 buy was Kenvue: 1,857,745 shares worth $37.3M.
- Mitsubishi UFJ Asset Management added most to Apple in Q3 2023, an estimated $187M increase.
- Mitsubishi UFJ Asset Management's biggest Q3 2023 reduction was Adobe, cutting an estimated $64.4M.
- Mitsubishi UFJ Asset Management fully exited Life Storage, Inc. in Q3 2023, selling an estimated $6.61M.
- Mitsubishi UFJ Asset Management's ten largest holdings make up 27% of its $49.4B portfolio in Q3 2023.
- Mitsubishi UFJ Asset Management opened 448 new positions and closed 14 in Q3 2023.
- Mitsubishi UFJ Asset Management's portfolio value rose 3.2% quarter-over-quarter to $49.4B.
Based on Mitsubishi UFJ Asset Management's 13F filing for Q3 2023, filed 7 Nov 2023.